These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11320392)

  • 1. Polysaccharide conjugate typhoid vaccine.
    Guerrant RL; Kosek M
    N Engl J Med; 2001 Apr; 344(17):1322-3. PubMed ID: 11320392
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.
    Canh DG; Lin FY; Thiem VD; Trach DD; Trong ND; Mao ND; Hunt S; Schneerson R; Robbins JB; Chu C; Shiloach J; Bryla DA; Bonnet MC; Schulz D; Szu SC
    Infect Immun; 2004 Nov; 72(11):6586-8. PubMed ID: 15501790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
    van Damme P; Kafeja F; Anemona A; Basile V; Hilbert AK; De Coster I; Rondini S; Micoli F; Qasim Khan RM; Marchetti E; Di Cioccio V; Saul A; Martin LB; Podda A
    PLoS One; 2011; 6(9):e25398. PubMed ID: 21980445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines.
    Peng ZH; Pan C; Sun P; Feng EL; Wu J; Zhu L; Peng QZ; Wang HL
    Yi Chuan; 2015 May; 37(5):473-9. PubMed ID: 25998436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Salmonella typhi Vi conjugate vaccine.
    Koul PA
    N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.
    Szu SC; Bystricky S; Hinojosa-Ahumada M; Egan W; Robbins JB
    Infect Immun; 1994 Dec; 62(12):5545-9. PubMed ID: 7960137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 14. The need & the issues related to new-generation typhoid conjugate vaccines in India.
    Vashishtha VM; Kalra A
    Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5-7 September 2012.
    Jones C; Lee CK; Ahn C; Shin J; Knezevic I
    Vaccine; 2013 Sep; 31(41):4466-9. PubMed ID: 23933367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence and immunogenicity of galactose-resistant variants of Salmonella typhi Ty21a.
    Saxena M; Percheson PB; Di Fabio JL
    J Infect Dis; 1993 Aug; 168(2):522-3. PubMed ID: 8336003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.